Evidence map›Paper›PMID 39152383›Full record

ArticleBMC infectious diseases2024

Treatment outcomes of standardized injectable shorter regimen for multi-drugs resistant tuberculosis in Ethiopia: a retrospective cohort study.

Daniel Legese Achalu, Adamu Bayissa Kiltu, Mekonnen Teferi, Foziya Getachew Mohammed, Birhanu Demeke Workneh, Kebede Abera Beyene, Gebremedhin Beedemariam Gebretekle, Eskinder Eshetu Ali

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniel Legese AchaluArmauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia.
Adamu Bayissa KiltuArmauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia.
Mekonnen TeferiArmauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia.
Foziya Getachew MohammedArmauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia.
Birhanu Demeke WorknehDepartment of Social and Administrative Pharmacy, Wollo University, Dessie, Ethiopia.
Kebede Abera BeyeneDepartment of Pharmaceutical and Administrative Sciences, University of Health Sciences and Pharmacy in St. Louis, St. Louis, MO, USA.
Gebremedhin Beedemariam GebretekleCanada's Drug and Health Technology Agency, Toronto, ON, Canada.
Eskinder Eshetu AliDepartment of Pharmaceutics and Social Pharmacy, Addis Ababa University, Addis Ababa, Ethiopia. eskinder.eshetu@aau.edu.et.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe injectable shorter multi-drug resistant tuberculosis (MDR-TB) regimen, has been reported to be less costly and more effective in the treatment of MDR-TB compared to the longer regimen. Ethiopia introduced the injectable shorter regimen (SR) in April 2018 following official recommendation by the World Health Organization (WHO) in 2016. While the WHO recommendation was based on evidence coming from extensive programmatic studies in some Asian and African countries, there is paucity of information on patient outcomes in the Ethiopian context. Thus, we aimed to assess the treatment outcomes and identify factors associated with the outcomes of MDR-TB patients on injectable SR.

methodsA multi-center facility-based retrospective cohort study was conducted in Ethiopia on 245 MDR-TB patients who were treated between April 2018 and March 2020. Data were collected from patients' medical records and analyzed using SPSS version 25. Descriptive statistics was used to summarize the results while inferential analysis was employed to investigate predictors of treatment outcomes and survival status.

resultsA total of 245 patients were included in the study, with 129 (52.7%) of them being female. Median age of the patients was 27 (IQR: 21-33). The overall treatment success rate was 87.8%, with 156 (63.7%) cured and 59 (24.1%) patients who completed treatment. The unfavorable outcomes accounted for 12.2%, with 16 (6.5%) treatment failure, 8 (3.3%) death and 6 (2.4%) lost to follow up. Majority of the unfavorable outcomes occurred during the early phase of therapy, with median time to event of 1.8 months (95% CI: 0.99-2.69). The use of khat (a green leafy shrub abused for its stimulant like effect) and being diagnosed with MDR-TB than rifampicin resistant only, were identified as independent factors associated with unfavorable outcomes.

conclusionThe injectable SR for MDR-TB was found to have positive treatment outcomes in the context of programmatic management in Ethiopia.

Indexed as

Antitubercular AgentsInjectionsTuberculosis, Multidrug-ResistantAdultEthiopiaFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeYoung AdultAntitubercular AgentsDrug-resistanceEthiopiaInjectable shorter regimenMDR-TBTreatment outcomesTuberculosis

Identifiers

PMID39152383
PMCPMC11329998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.